GB1449333A - Fractionation of blood - Google Patents
Fractionation of bloodInfo
- Publication number
- GB1449333A GB1449333A GB355774A GB355774A GB1449333A GB 1449333 A GB1449333 A GB 1449333A GB 355774 A GB355774 A GB 355774A GB 355774 A GB355774 A GB 355774A GB 1449333 A GB1449333 A GB 1449333A
- Authority
- GB
- United Kingdom
- Prior art keywords
- treated
- block copolymer
- serum
- concentration
- plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
1449333 Blood fractionation BAXTER LABORATORIES INC 25 Jan 1974 [30 Jan 1973] 3557/74 Heading A5B Blood protein fractions are prepared by (a) removing substantially all the blood coagulation factors (including fibrinogen, antihemophilic factor and prothrombin complex) from blood plasma or serum, (b) mixing with the treated plasma or serum 2-20 weight % of a block copolymer of ethylene oxide and propylene oxide containing at least 50 weight % of ethylene oxide residues and a poly(propylene oxide residue of molecular weight 950 or more and (c) recovering the blood protein fraction. In one embodiment, the plasma or serum is first treated with block copolymer at 10-20% concentration and pH 7 to 8 and the preciptate therefrom is treated with block copolymer at 3-13% concentration and pH 4 to 5 to provide an immunoglobulin complex. In another embodiment, the plasma or serum is first treated with the block copolymer at 10-20% concentration and pH 7 to 8 and the precipitate therefrom is treated with block copolymer at a concentration of 17-27% and a pH first of 7 to 8 and later of 4 to 5 to provide an albumin fraction. In a third embodiment, the plasma or serum is first treated with block copolymer at a concentration of 2-12% and a pH of 4 to 5 and the supernatant therefrom is treated with block copolymer at 14-24% to provide a precipitate for reconstitution to an organ perfusate.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32789373A | 1973-01-30 | 1973-01-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1449333A true GB1449333A (en) | 1976-09-15 |
Family
ID=23278536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB355774A Expired GB1449333A (en) | 1973-01-30 | 1974-01-25 | Fractionation of blood |
Country Status (10)
| Country | Link |
|---|---|
| JP (1) | JPS49102820A (en) |
| AU (1) | AU6495474A (en) |
| BE (1) | BE810217A (en) |
| CA (1) | CA984748A (en) |
| DE (1) | DE2403065A1 (en) |
| ES (1) | ES422767A1 (en) |
| FR (1) | FR2215241B1 (en) |
| GB (1) | GB1449333A (en) |
| IL (1) | IL44023A (en) |
| ZA (1) | ZA74350B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783441A (en) * | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3944391A (en) * | 1974-12-27 | 1976-03-16 | Preventive Systems, Inc. | In vitro process for detecting endotoxin in a biological fluid |
| IL49752A (en) * | 1975-07-09 | 1979-07-25 | Kabi Ab | Compositions having affinity for hepatitis virus and method for hepatitis virus removal or concentration |
| DK25877A (en) * | 1977-01-21 | 1978-08-15 | Nordisk Insulinlab | PROCEDURE FOR EXTRACTING PURE ALBUMIN FROM BLOOD PLASMA |
| JPS5843369B2 (en) * | 1977-09-10 | 1983-09-27 | 森六株式会社 | Serum protein fractionation method |
-
1974
- 1974-01-17 ZA ZA740350A patent/ZA74350B/en unknown
- 1974-01-20 IL IL44023A patent/IL44023A/en unknown
- 1974-01-21 JP JP49009169A patent/JPS49102820A/ja active Pending
- 1974-01-23 DE DE2403065A patent/DE2403065A1/en not_active Withdrawn
- 1974-01-25 GB GB355774A patent/GB1449333A/en not_active Expired
- 1974-01-28 BE BE140217A patent/BE810217A/en unknown
- 1974-01-29 CA CA191,229A patent/CA984748A/en not_active Expired
- 1974-01-29 FR FR7402807A patent/FR2215241B1/fr not_active Expired
- 1974-01-29 AU AU64954/74A patent/AU6495474A/en not_active Expired
- 1974-01-30 ES ES422767A patent/ES422767A1/en not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783441A (en) * | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS49102820A (en) | 1974-09-28 |
| BE810217A (en) | 1974-05-16 |
| IL44023A (en) | 1977-05-31 |
| DE2403065A1 (en) | 1974-08-01 |
| ES422767A1 (en) | 1976-06-01 |
| IL44023A0 (en) | 1974-05-16 |
| CA984748A (en) | 1976-03-02 |
| AU6495474A (en) | 1975-07-31 |
| ZA74350B (en) | 1974-11-27 |
| FR2215241A1 (en) | 1974-08-23 |
| FR2215241B1 (en) | 1977-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Marchesi et al. | Studies on the purification and characterization of human factor VIII | |
| Handin et al. | Antibody-induced von Willebrand's disease: a newly defined inhibitor syndrome | |
| Edwards et al. | Tri (n-butyl) phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives | |
| Müller-Eberhard et al. | Isolation of the anticomplementary protein from cobra venom and its mode of action on C3 | |
| Sixma et al. | Adhesion of platelets to human artery subendothelium: effect of factor VIII-von Willebrand factor of various multimeric composition | |
| Jaffe et al. | Synthesis of von Willebrand factor by cultured human endothelial cells | |
| Agre et al. | A molecular defect in two families with hemolytic poikilocytic anemia: reduction of high affinity membrane binding sites for ankyrin. | |
| Ohmori et al. | Electron microscopy of human factor VIII/Von Willebrand glycoprotein: effect of reducing reagents on structure and function. | |
| Yagi et al. | Monoclonal IgA and IgM in the serum of a single patient (SC) I. Sharing of individually specific determinants between IgA and IgM | |
| Mohri et al. | Acquired von Willebrand disease due to inhibitor of human myeloma protein specific for von Willebrand factor | |
| Fahey | Immunochemical studies of twenty mouse myeloma proteins: evidence for two groups of proteins similar to gamma and beta-2A globulins in man | |
| Higuchi et al. | Production of chemotactic factor for lymphocytes by neutral SH-dependent protease of rabbit PMN leukocytes from immunoglobulins, especially IgM | |
| Mosesson | A) Coagulation Proteins and Inhibitors: Cold-Insoluble Globulin (Clg), a Circulating Cell Surface Protein | |
| Mosesson et al. | Human platelet fibrinogen gamma chain structure | |
| GB1449333A (en) | Fractionation of blood | |
| Dawson et al. | Assay discrepancies with highly purified factor VIII concentrates | |
| Small et al. | Peptide maps of rabbit γG-immunoglobulin heavy chains controlled by Allelic Genes | |
| Clezardin et al. | Isolation of thrombospondin released from thrombinstimulated human platelets by fast protein liquid chromatography on an anion-exchange mono-q column | |
| Matsuda et al. | Cryofibrinogen in the plasma of patients with skin ulcerative lesions on the legs: a complex of fibrinogen and cold insoluble globulin | |
| Booth et al. | An altered platelet granule glycoprotein in patients with essential thrombocythemia. | |
| Gralnick et al. | Studies of the human factor VIII/von Willebrand's factor protein I. Comparison of the protein found in normal, von Willebrand's disease and hemophilia A | |
| Ziegler et al. | Genetic polymorphism of properdin factor B in the rhesus: evidence for single subunit structure in primates | |
| Sanchez-Avalos et al. | Degradation of fibrinogen by proteolytic enzymes | |
| Masci et al. | Fibrinolysis as a feature of disseminated intravascular coagulation (DIC) after Pseudonaja textilis textilis envenomation | |
| Pavirani et al. | Two independent domains of factor VIII co-expressed using recombinant vaccinia viruses have procoagulant activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| PCNP | Patent ceased through non-payment of renewal fee |